MAM
EIDX

Meeder Asset Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Meeder Asset Management’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-245
Closed -$3K – 1943
2018
Q4 		$3K Buy
245
+228
+1,341% +$2.88K ﹤0.01% 1546
2018
Q3 		$0 Buy
+17
New +$279 ﹤0.01% 1754

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Meeder Asset Management's EIDX Position: Q1 2019 in Review

Meeder Asset Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2019, closing a stake of 245 shares — an estimated $3K sold.

Meeder Asset Management first reported a position in EIDX in Q3 2018 and held it in 2 quarters. The position peaked at $3K in Q4 2018. 63 funds tracked by Wall St. Rank hold EIDX as of Q1 2019.

  • Meeder Asset Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Meeder Asset Management sold 245 Eidos Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $3K.
  • Meeder Asset Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 2 quarters.
  • Meeder Asset Management's Eidos Therapeutics, Inc. Common Stock position peaked at $3K in Q4 2018.
  • 63 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Meeder Asset Management's 13F filing for Q1 2019, filed 16 Apr 2019.